We've discovered 1 warning sign about Alnylam Pharmaceuticals. View them for free. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates by 56%. Looking ...

Alnylam analysts highlight Amvuttra's strong launch positioning and limited tariff risk, with bullish ratings maintained ...

ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.

Detailed price information for Precision Biosciences Inc (DTIL-Q) from The Globe and Mail including charting and trades.

Alnylam Pharmaceuticals Inc (ALNY) reports strong financial performance with significant growth in TTR franchise and ...

Christine Lindenboom; Chief Corporate Communications Officer; Alnylam Pharmaceuticals. Yvonne Greenstreet; Chief Executive Officer, Director; Alnylam Pharmaceuticals ...

The approvals of Onpattro, Givlaari, Oxlumo, and Leqvio combined with several partnerships have bolstered Alnylam's cash balance, and the company concluded fiscal 2024 with $2.69 billion in cash, cash ...

Discover Alnylam Pharmaceuticals' robust Q1 2025 earnings, highlighted by a 28% revenue growth and the successful launch of AMVUTTRA for ...

In its 10-Q report, Alnylam Pharmaceuticals stated that as of March 31, 2025, it had an accumulated deficit of $7.35 billion ...

With attention focused on their recently approved drugs for transthyretin amyloid cardiomyopathy (ATTR-CM), there was a ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,333.42 today based on a ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $57.5 million in its first quarter. The Cambridge, Massachusetts-based company said ...